Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis

Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PRACTECAL trial countries are considering programmatic uptake of 6-month, all-oral treatment regimens. We used a Mar...

Celý popis

Podrobná bibliografia

Vydané v:	PLOS global public health Ročník 2; číslo 12; s. e0001337
Hlavní autori:	Sweeney, Sedona, Berry, Catherine, Kazounis, Emil, Motta, Ilaria, Vassall, Anna, Dodd, Matthew, Fielding, Katherine, Nyang’wa, Bern-Thomas
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Public Library of Science (PLoS) 2022
ISSN:	2767-3375, 2767-3375
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!